Celltrion Archives | Be Korea-savvy
Celltrion Receives Approval to Sell Anticancer Biosimilar Vegzelma in Japan

Celltrion Receives Approval to Sell Anticancer Biosimilar Vegzelma in Japan

SEOUL, Sept. 27 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday it has received approval to sell its anticancer biosimilar Vegzelma in Japan. According to the company, Japan’s Ministry of Health, Labor and Welfare recently approved the sale of the biosimilar, also known as CT-P16, which referenced Switzerland-based Roche Holding’s blockbuster pill [...]

Celltrion Partners with Abpro of U.S. for Breast Cancer Treatment Development

Celltrion Partners with Abpro of U.S. for Breast Cancer Treatment Development

SEOUL, Sept. 21 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Wednesday it has signed a deal to jointly develop a bispecific breast cancer treatment candidate of Abpro Corp. of the United States. Under the deal, Celltrion and Abpro will work together for the development and market release of breast cancer treatment candidate [...]

Celltrion Opens R&D Office in Boston to Focus on New Drug Development

Celltrion Opens R&D Office in Boston to Focus on New Drug Development

SEOUL, Aug. 22 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. has opened a research and development (R&D) office in Boston to help accelerate its new drug development capabilities in the United States, according to company officials Monday. Celltrion completed the establishment of the Boston R&D office earlier this year and hired local office [...]

Celltrion Clinches 110 bln-won Drug Substance Supply Deal from Teva

Celltrion Clinches 110 bln-won Drug Substance Supply Deal from Teva

SEOUL, Aug. 19 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday it has secured a 110 billion-won (US$83 million) drug substance supply deal from Teva Pharmaceutical Industries Ltd. for use in producing the Israel-based generic drugmaker’s migraine medicine. Under the contract manufacturing organization (CMO) deal, Celltrion will provide drug substance [...]

Celltrion’s Autoimmune Disease Biosimilar to Land in U.S. in July 2023

Celltrion’s Autoimmune Disease Biosimilar to Land in U.S. in July 2023

SEOUL, April 27 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday it will begin sales of its autoimmune disease biosimilar Yuflymain in the United States in July 2023. The plan comes as Celltrion has settled a patent dispute with U.S. drugmaker AbbVie Inc. Yuflyma — a biosimilar referencing blockbuster drug Humira — [...]

Celltrion’s Autoimmune Disease Biosimilar Lands in S. Korea

Celltrion’s Autoimmune Disease Biosimilar Lands in S. Korea

SEOUL, March 2 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market. Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie Inc. — is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. [...]

Celltrion Expects COVID-19 Treatment Candidate to Show Efficacy Against Omicron

Celltrion Expects COVID-19 Treatment Candidate to Show Efficacy Against Omicron

SEOUL, Feb. 24 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. on Thursday anticipated its antibody treatment against COVID-19 under development would show efficacy against the omicron variant. Celltrion said that CT-P63 has maintained strong neutralizing ability against the omicron variant during pseudo-virus testing. The candidate treatment is currently under clinical trials. The announcement [...]

Celltrion’s Autoimmune Disease Biosimilar Wins Further Approval in Europe

Celltrion’s Autoimmune Disease Biosimilar Wins Further Approval in Europe

SEOUL, Feb. 22 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Tuesday that a high-concentration version of its autoimmune disease biosimilar Yuflyma has won approval from European drug authorities. The European Medicines Agency (EMA) gave the green light to Celltrion’s application to sell Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie [...]

Celltrion 2021 Net Soars 20 pct on Robust Overseas Sales

Celltrion 2021 Net Soars 20 pct on Robust Overseas Sales

SEOUL, Feb. 16 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday that its net profit jumped 20.1 percent on-year last year on the back of robust sales of its biosimilar products in overseas markets. Net profit came to 623.7 billion won (US$521.1 million) last year on a consolidated basis, compared [...]